Related Experiment Video
Updated: Oct 25, 2026

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
Design Considerations for Next-Generation Protein-Nucleic Acid Conjugates in Biorecognition and Therapy
Sasha B Ebrahimi1, Devleena Samanta2,3,4
1Drug Product Development, Emerging Drug Delivery Platforms, GSK, Collegeville, Pennsylvania19426, United States.
Abstract:
Proteins and nucleic acids represent nature's most versatile biomolecules. By leveraging the functionality of proteins and the programmability of nucleic acids, along with the exquisite recognition properties of both, protein-nucleic acid conjugates can unlock hybrid systems that outperform either component alone. In this Viewpoint, we discuss emerging applications of protein-nucleic acid conjugates in biorecognition and therapeutics. As detection tools, these structures can identify molecules in complex media and single living cells with high selectivity or amplify signals to create assays with ultralow limits of detection. For therapeutics, they can be engineered to regulate genes in a tissue-selective manner, act as immunotherapies, or form the basis of new biomaterials with unique in vitro and in vivo properties. We end by focusing on the outstanding challenges that remain before the full potential of these structures is realized in revolutionizing diagnostics and medicine.
Related Concept Videos
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Modified-Release Drug Delivery Systems: Site-Targeted
Phase II Conjugation Reactions: Overview
